Related Experiment Video
Updated: Jun 6, 2025

06:18
Author Spotlight: Segmentation and VR for Advanced Neurovascular Interventions
Published on: April 5, 2024
965
Advancing Precision Oncology with Digital and Virtual Twins: A Scoping Review.
Sebastian Aurelian Ștefănigă1, Ariana Anamaria Cordoș2,3, Todor Ivascu1
1Department of Computer Science, West University of Timișoara, Vasile Pârvan Blvd., No. 4, 300223 Timișoara, Romania.
Cancers
|November 27, 2024
Summary
Digital twins (DTHs) and virtual twins (VTHs) offer personalized oncology care but face challenges. Current technologies often lack real-world data and clinical validation, hindering widespread adoption.
Area of Science:
- Biomedical Engineering
- Computational Biology
- Oncology
Background:
- Digital twins (DTHs) and virtual twins (VTHs) are emerging technologies for precision medicine in healthcare.
- These patient-centric tools hold promise for revolutionizing cancer care.
Purpose of the Study:
- To map current DTH and VTH technologies in oncology.
- To summarize their technical solutions and assess credibility.
- To identify challenges and future directions for clinical implementation.
Main Methods:
- A systematic scoping review was conducted.
- Searched major bibliographic databases for relevant studies.
- Included 30 studies from 441 records, covering various cancers and applications.
Main Results:
- DTH and VTH applications span diagnosis, therapy, and monitoring across diverse cancers.
- Significant heterogeneity exists in technical approaches and outcomes.
- Most solutions rely on synthetic or limited real-world data, impacting reliability.
- Limited integration of real-time data and machine learning for predictive modeling was observed.
- Technical challenges include data integration, scalability, and ethical concerns (privacy, security).
- Clinical validation is often insufficient, leading to partial credibility.
Conclusions:
- Multidisciplinary collaboration is crucial to address technical and ethical hurdles.
- Substantial advancements are needed to transition DTH and VTH from experimental to clinical settings in personalized oncology.

